Episodes

  • ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More

    ASCO 2025 Insights Into HER2+ Breast Cancer: DESTINY-Breast06, SHR-A1811, Rechallenge With T-DXd Post Grade 1 ILD, and More
    Jul 2 2025
    Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallenging patients with T-DXd post grade 1 ILD.
    Show more Show less
    9 mins
  • Highlights From ATS 2025: New and Emerging Therapies, Biomarkers, and Imaging for ILDs

    Highlights From ATS 2025: New and Emerging Therapies, Biomarkers, and Imaging for ILDs
    Jun 27 2025
    Drs. Zaman and Podolanczuk discuss data for new and emerging therapies for ILD presented at ATS 2025, including nerandomilast, inhaled therapies for IPF and ILD, TNIK inhibitors, as well as new biomarkers and imaging for diagnosing ILDs.
    Show more Show less
    14 mins
  • Highlights From ATS 2025: Approach to the Evaluation and Management of Interstitial Lung Abnormalities—The Official ATS Clinical Statement

    Highlights From ATS 2025: Approach to the Evaluation and Management of Interstitial Lung Abnormalities—The Official ATS Clinical Statement
    Jun 26 2025
    Tanzira Zaman, MD and Elizabeth Volkmann, MD, MS discuss the new official American Thoracic Society Clinical Statement on the diagnosis and management of interstitial lung abnormalities which Dr. Podolanczuk presented at ATS 2025.
    Show more Show less
    10 mins
  • Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?

    Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?
    Jun 25 2025
    The FDA approved lenacapavir, a twice-yearly injectable PrEP shown to be 99% effective in preventing HIV, though high cost may limit global access. A phase 3 trial found that adding pembrolizumab to standard care improved event-free survival in head and neck cancer, especially in patients with high PD-L1 expression. MASLD-related deaths in the U.S. have quadrupled since 2006, rising most sharply in older adults and rural areas, and are expected to continue increasing.
    Show more Show less
    5 mins
  • Emerging and Future Biomarkers for Interstitial Lung Disease

    Emerging and Future Biomarkers for Interstitial Lung Disease
    Jun 24 2025
    Drs. Sood and Liu discuss emerging and investigational biomarkers for interstitial lung disease and their potential utility as predictors of progression or as tools for tailoring therapy.
    Show more Show less
    8 mins
  • Advances and Future Treatment Targets for Interstitial Lung Disease

    Advances and Future Treatment Targets for Interstitial Lung Disease
    Jun 23 2025
    Gabrielle Liu, MD, MS and Namita Sood, MD, FCCP discuss advances and future treatment targets for interstitial lung disease including some that are still under investigation.
    Show more Show less
    9 mins
  • Can an oral diabetes drug reduce hepatic scarring from MASH?

    Can an oral diabetes drug reduce hepatic scarring from MASH?
    Jun 20 2025
    A Chinese trial found dapagliflozin improved MASH outcomes, with higher resolution and fibrosis improvement rates than placebo. A JAMA Network Open survey showed 42% of abortion providers in ban states relocated, mostly to states with protections, highlighting growing care gaps. An oncology study found AI analysis of body composition better predicted chemo dose reductions than body surface area, especially in women.
    Show more Show less
    6 mins